CU Logo University of Colorado Anschutz Medical Campus

I'm Interested

Study: PIKture-01: First-in-Human Study of the PI3KalphaH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants with Advanced Solid Tumors and in Combination with Endocrine Therapy or HER2 Targeted Therapy in Participants with Advanced Breast Cancer
Please Select Your Affiliation with CU Anschutz

Thank you for expressing your interest in a research study and for taking the time to provide your information.

By clicking 'Submit', your information will be shared with the research team. Typically a member of the research team will contact you within 3 to 5 business days.

Please understand that:

  • The research team will need to determine whether you are eligible for the study. Clicking 'Submit' does not enroll you into the study, or guarantee that you qualify for the study.
  • It is always your choice to participate.

Thanks again. Volunteers such as yourself are at the core of our work.